Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Favipiravir in Male Ebola Survivors
NCT02739477Phase 2Terminated
- Sponsor
- Inserm
- Start
- Apr 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of favipiravir in Ebola virus disease (EVD), sponsored by Inserm. Started Apr 2016; status: terminated.
02
Drugs
favipiravir
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02739477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739477.